Want to see VTGN full AI Analyst Report?
VTGN Stock Chart & Stats
$0.23
<$0.01(1.46%)
At close: 4:00 PM EDT
$0.23
<$0.01(1.46%)
Day’s Range― - ―
52-Week Range$0.20 - $5.14
Previous CloseN/A
Volume374.63K
Average Volume (3M)1.23M
Market Cap
$10.83M
Enterprise Value-$21.23
Total Cash (Recent Filing)$31.73M
Total Debt (Recent Filing)$783.00K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 05, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding44,376,910
10 Day Avg. Volume1,055,596
30 Day Avg. Volume1,225,812
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.61
Price to Sales (P/S)17.15
P/FCF Ratio-0.33
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside334.78% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$950.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetDeclining absolute debt and a very low debt-to-equity ratio materially reduce near-term solvency risk and interest burden. For a cash‑consumptive clinical developer, low leverage gives management more flexibility to raise equity or structure financings without heavy fixed obligations, easing bankruptcy risk over the next several quarters.
Regulatory/Safety MilestoneMeeting ICH E1 exposure thresholds builds a durable safety database that supports longer-term dosing claims and potential NDA discussions. A growing tolerability dataset reduces regulatory and clinical de‑risking needs for multi‑dose programs and underpins a registrational pathway over the coming 2–6 months.
Strengthened Clinical LeadershipHiring a seasoned CMO with extensive neuroscience development experience strengthens trial design, operational execution, and regulatory engagement. Improved leadership continuity and domain expertise materially raise the odds of efficient Phase 3 conduct and credible interactions with regulators over the medium term.
Bears Say
Worsening Cash BurnSubstantially larger operating cash outflows signal persistent and worsening funding needs. For a pre‑commercial biotech, negative operating and free cash flow translate directly into near‑term reliance on external financing, increasing dilution risk and potentially forcing tradeoffs in program prioritization over the next several quarters.
Phase 3 Efficacy Setback / Strategic PivotA failed randomized Phase 3 endpoint imposes durable clinical and regulatory uncertainty: the pivot to multi‑dose registrational trials requires new trial design, more enrollment and time, and higher costs. This raises execution risk and delays potential commercialization for multiple quarters to years.
Listing / Share Price Compliance RiskAn active Nasdaq deficiency and time‑limited cure window create structural governance and financing pressure. Delisting risk can deter institutional investors, complicate capital raises, and consume management bandwidth — a sustained constraint while compliance must be restored.
VistaGen Therapeutics News
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.20 and its highest was $5.14 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $10.83M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.365 by $0.065.
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 44,376,910 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.365. Following the earnings report the stock price went up 0.376%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
VTGN Stock 12 Month Forecast
Average Price Target
$1.00
▲(334.78% Upside)
Technical Analysis
MacroGenics
―
Ovid Therapeutics
―
Spero Therapeutics
―
Inhibikase Therapeutics
―
Surrozen
―
Ownership Overview
0.38% Insiders
4.33% Mutual Funds
12.60% Other Institutional Investors
77.96% Public Companies and
Individual Investors